You are here

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis

 

Online download statistics by month:

Online download statistics by month: September 2023 to March 2026

AbstractFullPdf
Sep 2023527529138
Oct 202321721762
Nov 202316116149
Dec 202317517648
Jan 2024727338
Feb 2024717124
Mar 2024757662
Apr 2024747646
May 2024626239
Jun 2024686734
Jul 2024909244
Aug 20245554173
Sep 2024595993
Oct 2024656596
Nov 2024787942
Dec 2024737550
Jan 2025969665
Feb 202513913936
Mar 2025535338
Apr 2025696942
May 2025646652
Jun 2025373720
Jul 2025110
Mar 2026110
Total238223941291